Key clinical point: Overall survival data support 60 Gy of radiation with concurrent chemotherapy as standard of care for unresectable stage III NSCLC.
Major finding: Compared with high-dose RT, standard-dose RT yielded better median overall survival (28.7 vs. 20.3 months; P = .0072), 5-year overall survival (32.1% vs. 23%; P = .007), and 5-year progression-free survival (18.3% vs. 13%; P = .055).
Study details: Update of a phase 3 randomized controlled trial among 496 patients with unresectable stage III NSCLC comparing standard-dose RT (60 Gy) vs. high-dose RT (74 Gy) with concurrent chemotherapy, as well as cetuximab vs. no cetuximab (RTOG 0617 trial).
Disclosures: Dr. Bradley disclosed having a consulting or advisory role with AstraZeneca. The trial was supported by the National Cancer Institute and Eli Lilly.
Bradley JD et al. J Clin Oncol. 2019 Dec 16..